Metformin Downregulates the Insulin-IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma USC Cells Proliferation and Migration in p53-Dependent or -Independent MannersReportar como inadecuado




Metformin Downregulates the Insulin-IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma USC Cells Proliferation and Migration in p53-Dependent or -Independent Manners - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Accumulating epidemiological evidence shows that obesity is associated with an increased risk of several types of adult cancers, including endometrial cancer. Chronic hyperinsulinemia, a typical hallmark of diabetes, is one of the leading factors responsible for the obesity-cancer connection. Numerous cellular and circulating factors are involved in the biochemical chain of events leading from hyperinsulinemia and insulin resistance to increased cancer risk and, eventually, tumor development. Metformin is an oral anti-diabetic drug of the biguanide family used for treatment of type 2 diabetes. Recently, metformin was shown to exhibit anti-proliferative effects in ovarian and Type I endometrial cancer, although the mechanisms responsible for this non-classical metformin action remain unclear. The insulin-like growth factors IGFs play a prominent role in cancer biology and their mechanisms of action are tightly interconnected with the insulin signaling pathways. Given the cross-talk between the insulin and IGF signaling pathways, the aim of this study was to examine the hypothesis that the anti-proliferative actions of metformin in uterine serous carcinoma USC are potentially mediated via suppression of the IGF-I receptor IGF-IR pathway. Our results show that metformin interacts with the IGF pathway, and induces apoptosis and inhibition of proliferation and migration of USC cell lines with both wild type and mutant p53. Taken together, our results suggest that metformin therapy could be a novel and attractive therapeutic approach for human USC, a highly aggressive variant of endometrial cancer.



Autor: Rive Sarfstein, Yael Friedman, Zohar Attias-Geva, Ami Fishman, Ilan Bruchim, Haim Werner

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados